<DOC>
	<DOCNO>NCT02829827</DOCNO>
	<brief_summary>The purpose study evaluate safety tolerability , pharmacokinetics efficacy radiprodil abolish clinical spasm subject drug-resistant infantile spasm</brief_summary>
	<brief_title>A Study Radiprodil Subjects With Drug-resistant Infantile Spasms ( IS )</brief_title>
	<detailed_description />
	<mesh_term>Spasm</mesh_term>
	<mesh_term>Muscle Cramp</mesh_term>
	<mesh_term>Spasms , Infantile</mesh_term>
	<criteria>Subject male female 2 14 month age Onset spasm occur within 3 month study start The diagnosis infantile spasm ( IS ) Subject drugresistant IS Subject hematocrit great 60 Subject medical condition , opinion Investigator , could jeopardize would compromise subject 's ability participate study Subject history current condition predispose respiratory dysfunction Concomitant treatment felbamate Ketogenic diet Previous treatment IS StandardofCare ( StoC ) Clinically significant lab abnormality Clinically significant abnormality ECG , opinion Investigator , increase safety risk participate study Subject lethal potentially lethal condition IS , significant risk death 18 month age Body weight 4 kg Known history severe anaphylactic reaction secondary medication intake serious blood dyscrasia</criteria>
	<gender>All</gender>
	<minimum_age>2 Months</minimum_age>
	<maximum_age>14 Months</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Radiprodil</keyword>
	<keyword>Infantile spasm</keyword>
	<keyword>IS</keyword>
	<keyword>Infantile</keyword>
	<keyword>Spasms</keyword>
	<keyword>Epilepsy</keyword>
	<keyword>Paediatrics</keyword>
	<keyword>Drug-resistant</keyword>
	<keyword>West Syndrome</keyword>
	<keyword>Hypsarrhythmia</keyword>
</DOC>